Renal Cell Carcinoma
Conference Coverage
Combo delivers ‘impressive’ survival results in first-line RCC setting
Lenvatinib plus pembrolizumab improved progression-free and overall survival, compared with single-agent sunitinib.
Conference Coverage
Cabozantinib could be new standard for papillary RCC
Compared with sunitinib, cabozantinib prolonged progression-free survival in patients with metastatic disease.
Conference Coverage
CXR-Net: An AI-based diagnostic tool for COVID-19
The tool showed promise in a pilot study.
Conference Coverage
Asymptomatic screening for COVID-19 in cancer patients still debated
Less than 1% of cancer patients studied were COVID-19 positive on asymptomatic screening.
Conference Coverage
Managing cancer outpatients during the pandemic: Tips from MSKCC
MSKCC has established guiding principles on how to manage cancer patients during the pandemic.
Guidelines
COVID-19 vaccination in cancer patients: NCCN outlines priorities
Recommended timing of vaccination varies based on cancer and treatment type.
Conference Coverage
Model predicts acute kidney injury in cancer patients a month in advance
A machine learning algorithm identified nearly three-quarters of patients who went on to develop acute kidney injury.
Perspectives
COVID-19 vaccines and cancer patients: 4 things to know
From the Journals
Study shows no link between race and mortality in clear cell RCC
From the Journals
Four factors may predict better survival with cabozantinib in mRCC
The starting dose of cabozantinib, prior nephrectomy, disease risk group, and body mass index were all associated with survival in a real-world...
Feature
NHS England starts pilot trial of blood test for many cancers
Patients with head and neck, pancreatic, and other hard-to-spot cancers could soon have their disease picked up early with a simple blood test if...